Related Experiment Video
Updated: Mar 26, 2026
Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
Alteration of serum semaphorin 3B levels in preeclampsia
Hanzhi Wang1, Linxiang Jiang1, Bo Gao1
1Women's Hospital, School of Medicine, Zhejiang University, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China; Key Laboratory of Reproductive Genetics, Ministry of Education, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China; Key Laboratory of Women's Reproductive Health of Zhejiang Province, 1, Xueshi Road, Hangzhou, Zhejiang 310006, China.
Background:
Placental Semaphorin 3B (SEMA 3B) expression has been reported changed in preeclampsia and its possible involvement of in the disease proposed. We clarified the alterations of maternal SEMA 3B level in women suffering preeclampsia and pregnant women at gestational weeks of 16-20 before the onset of preeclampsia.
Methods:
Serum SEMA 3B concentration was measured with ELISA in preeclamptic women (preeclampsia) and normotensive women (control) in 3rd trimester, and also in pregnant women at gestational weeks of 16-20 who developed preeclampsia or had favorable pregnant outcome.
Results:
Serum SEMA 3B level was significantly increased in preeclampsia compared with control (P<0.001). There was a significant difference in serum SEMA 3B between mild and severe preeclampsia (P=0.04). Women with severe preeclampsia had significant serum SEMA 3B than women with mild preeclampsia. At gestational weeks of 16-20, serum SEMA 3B was significantly higher in women who developed preeclampsia than women who had normal pregnant outcome (P<0.001).
Conclusions:
Maternal SEMA 3B level increased in preeclampsia before the onset of manifestations, indicating that SEMA 3B plays a role in the pathogenesis of preeclampsia.
